76 Chapter 3 15. Bigal ME and Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology. 2008, p. 848-855. 16. Pijpers JA, Kies DA, Louter MA, et al. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. Brain. 2019, p. 1203-1214. 17. Ashina S, Serrano D, Lipton RB, et al. Depression and risk of transformation of episodic to chronic migraine. J Headache Pain. 2012/09/26 ed. 2012, p. 615-624. 18. Lipton RB, Fanning KM, Buse DC, et al. Migraine progression in subgroups of migraine based on comorbidities. Neurology. 2019, p. e2224-e2236. 19. Stam AH, de Vries B, Janssens AC, et al. Shared genetic factors in migraine and depression: evidence from a genetic isolate. Neurology. 2010/01/15 ed. 2010, p. 288-294. 20. Eriksen MK, Thomsen LL, Andersen I, et al. Clinical characteristics of 362 patients with familial migraine with aura. Cephalalgia. 2004/06/16 ed. 2004, p. 564-575. 21. Viana M, Sances G, Linde M, et al. Clinical features of migraine aura: Results from a prospective diary-aided study. Cephalalgia. 2016/08/31 ed. 2017, p. 979-989. 22. Kim KM, Kim BK, Lee W, et al. Prevalence and impact of visual aura in migraine and probable migraine: a population study. Sci Rep. 2022/01/12 ed. 2022, p. 426. 23. van de Graaf DL, Schoonman GG, Habibović M, et al. Towards eHealth to support the health journey of headache patients: a scoping review. J Neurol. 2020/06/13 ed. 2021, p. 36463665. 24. Wang YF, Fuh JL, Chen SP, et al. Clinical correlates and diagnostic utility of osmophobia in migraine. Cephalalgia. 2012/10/06 ed. 2012, p. 1180-1188.
RkJQdWJsaXNoZXIy MjY0ODMw